1. Home
  2. AEVA vs TBPH Comparison

AEVA vs TBPH Comparison

Compare AEVA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEVA

Aeva Technologies Inc.

HOLD

Current Price

$15.99

Market Cap

1.0B

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.79

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEVA
TBPH
Founded
2019
2013
Country
United States
United States
Employees
239
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
824.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
AEVA
TBPH
Price
$15.99
$16.79
Analyst Decision
Strong Buy
Buy
Analyst Count
4
6
Target Price
$26.50
$18.40
AVG Volume (30 Days)
1.1M
414.8K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
279.13
EPS
N/A
2.06
Revenue
N/A
$15,386,000.00
Revenue This Year
$85.37
$8.46
Revenue Next Year
$132.72
N/A
P/E Ratio
N/A
$7.97
Revenue Growth
N/A
N/A
52 Week Low
$6.86
$8.33
52 Week High
$38.79
$21.03

Technical Indicators

Market Signals
Indicator
AEVA
TBPH
Relative Strength Index (RSI) 58.94 57.45
Support Level $15.78 $13.41
Resistance Level $17.27 $17.24
Average True Range (ATR) 1.15 0.41
MACD 0.25 0.02
Stochastic Oscillator 59.82 59.28

Price Performance

Historical Comparison
AEVA
TBPH

About AEVA Aeva Technologies Inc.

Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: